Helping NASH Study Sites to Succeed:
Insights into Operational Best Practices
About this webinar
Non-alcoholic steatohepatitis (NASH) is a complicated disease that requires expertise across a broad spectrum of therapeutic areas, including hepatology, gastroenterology and endocrinology. As the prevalence of NASH continues to rise and the number of clinical trials is increasing, there is greater demand for patients and increased competition for site resources. In this challenging landscape, how can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies? We will provide perspectives on how to best partner with sites now and in the future to meet the growing demand for NASH patients while delivering high quality results.
Get insights and feedback from our extensive NASH study experience, and the findings from ICON’s recent survey of more than 2,000 sites across 30 countries. We will discuss the operational data compiled and shared through questionnaire responses on best practices for NASH study sites.
Who should attend
This program is intended for professionals from NASH pharmaceutical, biotech, and medical device companies involved in:
- NASH Clinical Development
- Patient Recruitment
- Site Management
- Imaging
What you will learn
Participants will gain insights on:
- How to best support global NASH sites to succeed in a competitive environment
- Optimising the operational strength of study sites to collectively support the NASH pipeline
- How understanding global and regional nuances can enhance NASH site patient recruitment and operational strategy
Featured Speakers
Debbie Marshall
Debbie Marshall has significant NASH experience, including seven NASH studies over the past five years, enrolling 888 patients in eight countries (US, CAN, UK, France, Germany, Italy, New Zealand, and Spain). Through her extensive NASH experience, Debbie maintains relationships with many US, UK, German, and Canadian NASH investigators. Additionally, she has collaborated with radiology and histopathology central readers, fostering key relationships throughout the NASH community.
Partner for this event
ICON plc
ICON plc is a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,200 employees.
Related webinars
More from Icon.
Strategic approaches for early clinical trials in neurodegenerative diseases
Insights into first-in-human study design of oligonucleotides
When patients lead: Breaking barriers in ultra-rare disease drug development
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Becoming a sponsor of choice for high-performing sites
Riding the data wave: How pharma can navigate disruptions in open claims
Beyond the bench: The advantages of GMP over USP compounding in early phase development
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies
Introducing ICON Strategic Solutions FSP Services: How This Model Supports Sponsors in Korea
From Fragmented to Fluid: A Deep Dive into Claims Data Innovation
Get ready for a new wave of clinical trials in Schizophrenia: how Sites and Sponsors can avoid conceptual mistakes